Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07336238 · ClinicalTrials.gov registry record · Phase 2
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
A Phase 2 study, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT07336238 is a Phase 2 study that is actively recruiting participants, run by University of Washington. The registered enrollment target is 18 participants.
The verdict
NCT07336238, a Phase 2 study, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.
Interventions
- BEHAVIORAL Psychotherapy
- OTHER Survey Administration
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-05-19 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07336238
The ClinicalTrials.gov registry entry for NCT07336238 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Psychotherapy is the first listed.
NCT07336238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07336238 about?
NCT07336238 is a clinical study titled "Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies". This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic ...
What is the current status of trial NCT07336238?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2026-05-19. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07336238?
The interventions under investigation include: Psychotherapy (BEHAVIORAL), Survey Administration (OTHER), Psilocybin (DRUG).
Who is sponsoring clinical trial NCT07336238?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.